MELOXICAM
| Brand name | ANJESO |
|---|---|
| Active ingredient | MELOXICAM |
| Strength | 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | February 2020 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 11458145 | March 2039 | use U-3318 |
| 10881663 | March 2039 | use U-3038 |
| 10709713 | May 2030 | use U-2750 |
| 11253478 | May 2030 | product |
| 9974746 | May 2030 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.